IONIS EVP sells 3,069 shares at $80 each

IONIS PHARMACEUTICALS INC executive Patrick R. O’Neil sold 3,069 shares of common stock in an open-market transaction.

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC executive Patrick R. O’Neil sold 3,069 shares of common stock in an open-market transaction. The shares were sold at $80.00 per share, and he now directly holds 61,470 shares following the sale.

The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which typically means it was scheduled in advance rather than timed discretionarily.

Insights

Insider trading and corporate governance analyst

Pre-planned, modest insider sale with significant remaining holdings.

Executive Vice President and General Counsel Patrick R. O’Neil sold 3,069 shares of IONIS PHARMACEUTICALS INC common stock at $80.00 per share in an open-market transaction. After this sale, he continues to directly own 61,470 shares, indicating a substantial remaining position.

The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Such plans are set up in advance, so the timing of the sale is generally viewed as routine portfolio management rather than a reaction to new information.

There were no derivative exercises or tax-withholding transactions reported, and no remaining derivative positions are shown in this filing. Overall, this appears to be a standard, pre-planned disposition rather than a thesis-changing event.

Insider Trade Summary 10b5-1

Net Seller: 3,069 shares

Net Sell 1 txn

Insider O'NEIL PATRICK R.

Role EVP CLO & General Counsel

Sold 3,069 shs ($246K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,069	$80.00	$246K

Holdings After Transaction: Common Stock — 61,470 shares (Direct)

Footnotes (1)

1. F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025.

Key Figures

Shares sold: 3,069 shares Sale price: $80.00 per share Shares held after sale: 61,470 shares +2 more

5 metrics

Shares sold 3,069 shares Open-market sale on June 26, 2026

Sale price $80.00 per share Common stock transaction price

Shares held after sale 61,470 shares Direct ownership following transaction

Net share change -3,069 shares Net-sell direction in transaction summary

Rule 10b5-1 plan adoption date December 8, 2025 Plan governing this sale

Key Terms

Rule 10b5-1 Trading Plan, open-market sale, Form 4, common stock

4 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What insider transaction did IONIS PHARMACEUTICALS (IONS) report for Patrick R. O’Neil?

IONIS PHARMACEUTICALS reported that executive Patrick R. O’Neil sold 3,069 shares of common stock. The shares were sold in an open-market transaction at $80.00 per share, and this trade is disclosed in a Form 4 insider filing.

How many IONIS PHARMACEUTICALS (IONS) shares does Patrick R. O’Neil hold after this Form 4 sale?

After the reported sale, Patrick R. O’Neil directly holds 61,470 shares of IONIS PHARMACEUTICALS common stock. This post-transaction balance is disclosed in the Form 4 and shows he retains a significant equity stake in the company.

Was the IONIS PHARMACEUTICALS (IONS) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the 3,069-share sale was made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Such pre-arranged plans schedule trades in advance, making the timing more mechanical and less discretionary.

What price did Patrick R. O’Neil receive for his IONIS PHARMACEUTICALS (IONS) share sale?

Patrick R. O’Neil sold 3,069 IONIS PHARMACEUTICALS common shares at a price of $80.00 per share. This per-share sale price is reported directly in the Form 4 insider trading disclosure for the transaction.

What role does Patrick R. O’Neil hold at IONIS PHARMACEUTICALS (IONS)?

Patrick R. O’Neil serves as Executive Vice President, Chief Legal Officer and General Counsel at IONIS PHARMACEUTICALS. His senior leadership position makes his equity transactions subject to Form 4 reporting as a company officer.

Does this IONIS PHARMACEUTICALS (IONS) Form 4 show any option exercises or derivative trades?

No. The Form 4 only reports an open-market sale of common stock and shows no derivative transactions or option exercises. The derivative summary section is empty, indicating no options or similar instruments were exercised in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 05:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'NEIL PATRICK R.

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP CLO & General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		S		3,069(1)	D	$80	61,470	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025.

	Patrick R. O'Neil	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)